Novel CD19-KIRS2/Dap12-BB CAR-T Treatment for 3 Patients with Relapsed and Refractory B-Cell Tumors.
10.19746/j.cnki.issn.1009-2137.2023.06.040
- Author:
Sheng-Wei JI
1
;
Tian HUA
1
;
Jiao-Jiao WANG
1
;
Ling-Yan SHAO
1
;
Zi-Han CHEN
1
;
Jia-Ying LIU
1
;
Hai CHENG
1
;
Wei CHEN
1
;
Cai SUN
1
;
Xue WANG
1
;
Kai-Lin XU
1
;
Jiang CAO
2
Author Information
1. Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou 221002, Jiangsu Province, China.
2. Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou 221002, Jiangsu Province, China.E-mail: zimu05067@163.com.
- Publication Type:Journal Article
- Keywords:
chimeric antigen receptor T cells;
B-cell malignancy;
KIRS2/Dap12
- MeSH:
Humans;
Receptors, Chimeric Antigen;
Immunotherapy, Adoptive;
Burkitt Lymphoma;
Antigens, CD19;
Neoplasm, Residual;
Adaptor Proteins, Signal Transducing
- From:
Journal of Experimental Hematology
2023;31(6):1860-1865
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the safety and efficacy of novel CD19-KIRS2/Dap12-BB chimeric antigen receptor T cells (CAR-T cells) in the treatment of relapsed/refractory B-cell malignancy (R/R BCM).
METHODS:Three patients with R/R BCM treated with novel CD19-KIRS2/Dap12-BB CAR-T cells from June 2020 to November 2020 were enrolled, including 1 case of B-cell acute lymphoblastic leukaemia (B-ALL) and 2 cases of non-Hodgkin's lymphoma (NHL), and the efficacy and adverse reactions were observed.
RESULTS:After CAR-T cells infusion, patient with B-ALL achieved complete remission (CR) and minimal residual disease (MRD) turned negative, and 2 patients with NHL achieved partial remission (PR). Grade 2 cytokine release syndrome (CRS) occurred in B-ALL patient, grade 1 CRS occurred in 2 NHL patients, and grade II to IV hematologic adverse reactions occurred in 3 patients, all of which were controllable and reversible. The progression-free survival (PFS) of the 3 patients was 143, 199, and 91 days, and overall survival (OS) was 282, 430, and 338 days, respectively.
CONCLUSION:The novel CD19-KIRS2/Dap12-BB CAR-T cells in treatment of 3 patients with R/R BCM have significant short-term efficacy and controllable adverse reactions, but the long-term efficacy needs to be further improved.
